Omeros Corp., of Seattle, said OMS824, in the latest cohort of healthy male subjects enrolled in the phase I trial, achieved a high of approximately 70-percent engagement at phosphodiesterase 10 (PDE10) without evidence of extrapyramidal symptoms. Read More
Biolinerx Ltd., of Jerusalem, reported positive preclinical results for BL-8040 in a third indication, as a treatment for chronic myeloid leukemia (CML). Read More
Incyte Corp., of Wilmington, Del., reported for the full year ended Dec. 31, 2013, net product revenues of Jakafi (ruxolitinib) were $235.4 million as compared to $136 million for the same period in 2012. Read More
A multinational team of researchers has deciphered the molecular reason behind why mutations in the sortilin-related receptor with A-type repeats (SORLA) raise the risk for Alzheimer’s disease – and have shown that by increasing its levels in the brains of mice, they were able to lower levels of amyloid-beta protein. Read More
With preliminary phase IIa data in hand for its postoperative pain treatment PRF-110, Israeli specialty pharmaceutical firm Painreform Ltd. is now seeking takers for the product, which has a 505(b)(2) approval pathway in the U.S. Read More
NEW YORK – With so many big pharmas jumping on the rare disease bandwagon in the past few years, it might sound as though developing drugs for rare and orphan diseases was the pathway of choice. Read More
The question of whether ordinary equity offerings are better than the sale of convertible notes as a financing method found differing answers from thriving Ironwood Pharmaceuticals Inc. and troubled intravenous-iron specialist Amag Pharmaceuticals Inc., both of which raised $175 million. Read More
